Calculate exact syringe units for the GLOW Blend (BPC-157 + TB-500 + GHK-Cu) pre-mixed blend. The dose shown is from the combined vial — no separate math needed.
Adjust vial, water, and dose — answer updates live
All three take the same units for the same dose. A smaller barrel just spreads it over more space.
on a U-100 syringe for a 1.4mg dose
Assumes the pre-blended 70 mg vial, 5:1:1 GHK-Cu : BPC-157 : TB-500.
Add 3 mL BAC water to your 70 mg vial. Draw to 6.0 units on a U-100 syringe for a 1.4mg dose. This vial will last 50 doses.
Copy link saves these numbers in the address. Anyone who opens it sees the same draw.
Never miss a dose — 1.4mg daily, draw 6.0 units on U-100 syringe.
Tracking needs a free account, about 20 seconds
The calculator stays free without one
Over 4,000 human genes respond to a single copper-binding tripeptide. That tripeptide is GHK-Cu, and the GLOW Blend builds an entire healing protocol around it. Full name: BPC-157 + TB-500 + GHK-Cu (also called the triple healing stack). No CAS number exists for the combination. BPC-157 upregulates VEGF to build new blood vessels at injury sites. It modulates nitric oxide for vascular protection and activates the FAK-paxillin pathway for tendon and ligament repair. TB-500 (the active fragment of Thymosin Beta-4) upregulates actin, a cell-building protein that moves repair cells to wound sites. It also drops pro-inflammatory cytokines across the entire body. GHK-Cu delivers copper ions to tissue, triggering collagen I and III synthesis and decorin expression for organized (not fibrotic) tissue remodeling. Community adoption sits at roughly 200+ Reddit threads and a 4.3/5 sentiment score. Users consistently describe higher-quality healed tissue compared to BPC-157 plus TB-500 alone, with less scar formation and visible skin improvements by week four. The primary complaint: budget pre-mixed vials deliver roughly 200 mcg of GHK-Cu, which is 5 to 10 times below the community-effective dose of 1 to 2 mg daily. The honest assessment: zero human combination trials exist. BPC-157 has one published human pilot (PMID 40131143, n=2, IV only). TB-500 has no human data at all for the subcutaneous route; the Phase I PK often cited (PMC8419156) studied recombinant full-length thymosin beta-4 given IV. GHK-Cu evidence is primarily in vitro and animal. Promising preclinical data and strong community consensus, but the clinical gap is real.
One page: what is in the vial, the dose each tier delivers per component, syringe units, cycling, and where every number comes from.
Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
